IFM Investors Pty Ltd Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

IFM Investors Pty Ltd boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 9.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,919 shares of the biopharmaceutical company's stock after acquiring an additional 2,219 shares during the period. IFM Investors Pty Ltd's holdings in Alnylam Pharmaceuticals were worth $7,129,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Whipplewood Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares during the last quarter. Larson Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $28,000. Finally, Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded up $3.11 on Wednesday, reaching $320.61. 753,943 shares of the stock were exchanged, compared to its average volume of 856,619. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70. The firm has a market capitalization of $41.80 billion, a price-to-earnings ratio of -153.40 and a beta of 0.23. The business has a 50 day moving average price of $297.55 and a two-hundred day moving average price of $267.35. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ALNY. Wall Street Zen upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Scotiabank raised their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target for the company. Finally, Bank of America raised their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $341.91.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,978,088. This represents a 28.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.